By SPC News Staff
The monoclonal antibody dupilumab (Dupixent, Sanofi/Regeneron) significantly reduced exacerbations in children ages 6 to 11 years with uncontrolled moderate to severe asthma, according to research presented at the ATS 2021 International Conference (abstract A1204).
In the multicenter, double-blind VOYAGE trial, investigators enrolled 408 children ages 6 to 11 with uncontrolled moderate to severe asthma. The researchers performed prespecified primary analyses in two groups in the